AIM: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT. RESULTS: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%. CONCLUSION: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.

Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience / Meattini, Icro; Desideri, Isacco; DI CATALDO, Vanessa; Francolini, Giulio; De Luca Cardillo, Carla; Scotti, Vieri; Loi, Mauro; Detti, Beatrice; Mangoni, Monica; Agresti, Benedetta; Baldazzi, Valentina; Greto, Daniela; Casella, Donato; Bernini, Marco; Sanchez, Luis Jose; Orzalesi, Lorenzo; Nori, Jacopo; Fambrini, Massimiliano; Bianchi, Simonetta; Livi, Lorenzo. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 12:9(2016), pp. 1117-1124. [10.2217/fon-2015-0059]

Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience

BERNINI, MARCO;
2016

Abstract

AIM: This study evaluates, for the first time, the safety of eribulin in metastatic breast cancer patients concomitantly treated with palliative radiotherapy (RT). Patients & materials: A total of 17 patients were pretreated for metastatic breast cancer. Patients received eribulin mesylate and bone RT. RESULTS: The most frequent grade 3 hematologic adverse events were neutropenia (56%) and anemia (20%). Mean pain score decreased from 2 (baseline) to 0.7 (end of observation). Analgesic score remained stable (1.8 vs 1.6). Bone pain scores dropped within a few weeks and remained below baseline values throughout the analysis. The overall response rate was 29%, and the clinical benefit rate was 59%. CONCLUSION: Eribulin is characterized by a manageable safety profile also when combined with palliative RT.
2016
12
9
1117
1124
Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience / Meattini, Icro; Desideri, Isacco; DI CATALDO, Vanessa; Francolini, Giulio; De Luca Cardillo, Carla; Scotti, Vieri; Loi, Mauro; Detti, Beatrice; Mangoni, Monica; Agresti, Benedetta; Baldazzi, Valentina; Greto, Daniela; Casella, Donato; Bernini, Marco; Sanchez, Luis Jose; Orzalesi, Lorenzo; Nori, Jacopo; Fambrini, Massimiliano; Bianchi, Simonetta; Livi, Lorenzo. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 12:9(2016), pp. 1117-1124. [10.2217/fon-2015-0059]
Meattini, Icro; Desideri, Isacco; DI CATALDO, Vanessa; Francolini, Giulio; De Luca Cardillo, Carla; Scotti, Vieri; Loi, Mauro; Detti, Beatrice; Mangoni, Monica; Agresti, Benedetta; Baldazzi, Valentina; Greto, Daniela; Casella, Donato; Bernini, Marco; Sanchez, Luis Jose; Orzalesi, Lorenzo; Nori, Jacopo; Fambrini, Massimiliano; Bianchi, Simonetta; Livi, Lorenzo
File in questo prodotto:
File Dimensione Formato  
Meattini et al 2016 Fut Oncol_eribulin.pdf

Accesso riservato

Dimensione 2.06 MB
Formato Adobe PDF
2.06 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1331699
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact